Developing a Passive Dosing Method for Acute Aquatic Toxicity Tests of Cationic Surfactant Benzalkoniums (BACs).

Benzalkonium chlorides (BACs) have been of environmental concern due to their widespread use and potential harm. However, challenges arise in defining and controlling the exposure concentration (Cw) in aquatic toxicity tests involving BACs with a long alkyl chain (i.e., #C > 14). To address this, a novel passive dosing method was introduced in the 48 h-acute ecotoxicity test on Daphnia magna and compared to the conventional solvent-spiking method in terms of Cw stability and toxicity results. Among 13 sorbent materials tested for their sorption capacity, poly(ether sulfone) (PES) membrane was an optimal passive dosing reservoir, with equilibrium desorption of BACs to water achieved within 24 h. The Cw of BACs remained constant in both applied dosing methods during the test period. However, the Cw in solvent-spiking tests was lower than the nominal concentration for long-chain BACs, particularly at low exposure concentrations. Notably, the solvent-spiking tests indicated that the toxicity of BACs increased with alkyl chain length from C6 to 14, followed by a decline in toxicity from C14 to 18. In contrast, the passive dosing method displayed similar or slightly increasing toxicity levels of BACs from C14 to C18, indicating higher toxicity of C16 and C18-BACs than that inferred by the solvent spiking test. These findings emphasize the potential of applying this innovative passive dosing approach in aquatic toxicity tests to generate reliable and accurate toxicity data and support a comprehensive risk assessment of cationic surfactants.

Effect of Mass Fraction on Leaching Kinetics of Hydrophobic Ultraviolet Stabilizers in Low-Density Polyethylene.

The leaching kinetics of five hydrophobic ultraviolet (UV) stabilizers from low-density polyethylene (LDPE) (micro)fibers into water was evaluated in this study, with variation of the mass fraction (ω = 0.1-2.0 wt %) of the stabilizers. A one-dimensional convection-diffusion model for a cylindrical geometry, requiring partitioning between the LDPE fibers and water (KLDPEw) and the internal diffusion coefficients (DLDPE), was used to evaluate the leaching process and the leaching half-life of the target UV stabilizers at ω < 0.5 wt % (Case I). Diffusion through the aqueous boundary layer is the rate-determining step, and the leaching half-life is predicted to be very long (a few months to years) under unaffected conditions. When the UV stabilizers are supersaturated within LDPE fibers (i.e., ω > 0.5 wt %, Case II), the possible formation of a surficial crystal layer of the additives on the LDPE fiber extends the time scale for leaching compared to that in Case I due to the requirement of overcoming the crystallization energy. This study provides a fundamental understanding of the leaching profiles of plastic additives for assessing their potential chemical risks in aquatic environments; further studies under the relevant environmental conditions are required.

Induction of Meal-related Symptoms as a Novel Mechanism of Action of the Duodenal-Jejunal Bypass Sleeve.

BACKGROUND: Treatment with a duodenal-jejunal bypass sleeve (DJBS) induces clinically significant weight loss, but little is known about the mechanisms of action of this device. AIM: The aim of this study was to characterize the mechanisms of action of the DJBS and determine the durability of weight loss and metabolic improvements. MATERIALS AND METHODS: We studied a cohort of 19 subjects with severe obesity and type 2 diabetes (baseline body mass index: 43.7±5.3 kg/m). Anthropometry, body composition, blood pressure, biochemical measures, and dietary intake were monitored for 48 weeks after DJBS implantation, and then for 1 year after device removal. Gastric emptying and triglyceride absorption were measured at baseline, 8 weeks after implant, and within 3 weeks of device explant. Visceral sensory function was assessed at baseline, 4 weeks after implant, and within 3 weeks after explant. RESULTS: Significant weight loss (P<0.01) occurred following DJBS placement, with a mean weight reduction of 17.0±6.5% at 48 weeks. The symptom burden following a standardized nutrient challenge was increased after DJBS implantation (P<0.05), returning to baseline after DJBS removal. Neither gastric emptying nor triglyceride absorption changed with the device in situ. A significant reduction in energy intake was observed [baseline: 7703±2978 kJ (1841±712 kcal), 24 weeks: 4824±2259 kJ (1153±540 kcal), and 48 weeks: 4474±1468 kJ (1069±351 kcal)]. After 1 year, anthropometry remained significantly improved, but there was no durable impact on metabolic outcomes. CONCLUSIONS: DJBS treatment resulted in substantial weight loss. Weight loss is related to reduced caloric intake, which seems linked to an augmented upper gastrointestinal symptom response, but not altered fat absorption.

Antagonism of protease-activated receptor 2 protects against experimental colitis.

Many trypsin-like serine proteases such as ß-tryptase are involved in the pathogenesis of colitis and inflammatory bowel diseases. Inhibitors of individual proteases show limited efficacy in treating such conditions, but also probably disrupt digestive and defensive functions of proteases. Here, we investigate whether masking their common target, protease-activated receptor 2 (PAR2), is an effective therapeutic strategy for treating acute and chronic experimental colitis in rats. A novel PAR2 antagonist (5-isoxazoyl-Cha-Ile-spiro[indene-1,4'-piperidine]; GB88) was evaluated for the blockade of intracellular calcium release in colonocytes and anti-inflammatory activity in acute (PAR2 agonist-induced) versus chronic [2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced] models of colitis in Wistar rats. Disease progression (disease activity index, weight loss, and mortality) and postmortem colonic histopathology (inflammation, bowel wall thickness, and myeloperoxidase) were measured. PAR2 and tryptase colocalization were investigated by using immunohistochemistry. GB88 was a more potent antagonist of PAR2 activation in colonocytes than another reported compound, N¹-3-methylbutyryl-N4-6-aminohexanoyl-piperazine (ENMD-1068) (IC50 8 µM versus 5 mM). Acute colonic inflammation induced in rats by the PAR2 agonist SLIGRL-NH2 was inhibited by oral administration of GB88 (10 mg/kg) with markedly reduced edema, mucin depletion, PAR2 receptor internalization, and mastocytosis. Chronic TNBS-induced colitis in rats was ameliorated by GB88 (10 mg/kg/day p.o.), which reduced mortality and pathology (including colon obstruction, ulceration, wall thickness, and myeloperoxidase release) more effectively than the clinically used drug sulfasalazine (100 mg/kg/day p.o.). These disease-modifying properties for the PAR2 antagonist in both acute and chronic experimental colitis strongly support a pathogenic role for PAR2 and PAR2-activating proteases and therapeutic potential for PAR2 antagonism in inflammatory diseases of the colon.

Ecotoxicological effects of micro- and nanoplastics on terrestrial food web from plants to human beings.

Micro- and nanoplastics (MNPs) are present in almost all environmental compartments. Terrestrial soils are major environmental reservoirs for MNPs, but the ecotoxicological effects of MNPs on terrestrial biota remain relatively understudied. In this review, we collated findings of previous research on the uptake and impact of MNPs in terrestrial organisms, including flora, fauna, and human beings. Terrestrial plants can take up MNPs via the roots or leaves and translocate them to other parts. MNPs have been detected in the gastrointestinal tracts or feces of many terrestrial animals, including some high trophic-level predators, indicating the incidence of direct ingestion or trophic transfer of MNPs. The presence of MNPs in food items and human feces combines to verify human intake of MNPs via the dietary pathway. Exposure to MNPs can cause diverse effects on terrestrial organisms, including alterations in growth performance, oxidative stress, metabolic disturbance, cytotoxicity, genotoxicity, and mortality. The biological internalization and impact of MNPs are influenced by the physicochemical properties of MNPs (e.g., particle size, polymer type, surface chemistry, and exposure concentrations) and the physiology of the species. MNPs can also affect the bioavailability of co-occurring intrinsic or extrinsic contaminants to terrestrial biota, but their specific role is under dispute. Finally, we underlined the current research gaps and proposed several priorities for future studies.

Leaching of microplastic-associated additives in aquatic environments: A critical review.

Microplastic pollution has attracted significant attention as an emerging global environmental problem. One of the most important issues with microplastics is the leaching of harmful additives. This review summarizes the recent advances in the understanding of the leaching phenomena in the context of the phase equilibrium between microplastics and water, and the release kinetics. Organic additives, which are widely used in plastic products, have been introduced because they have diverse physicochemical properties and mass fractions in plastics. Many theoretical and empirical models have been utilized in laboratory and field studies. However, the partition or distribution constant between microplastics and water (Kp) and the diffusivity of an additive in microplastics (D) are the two key properties explaining the leaching equilibrium and kinetics of hydrophobic organic additives. Because microplastics in aquatic environments undergo dynamic weathering, leaching of organic additives with high Kp and/or low D cannot be described by a leaching model that only considers microplastic and water phases with a fixed boundary. Surface modifications of microplastics as well as biofilms colonizing microplastic surfaces can alter the leaching equilibrium and kinetics and transform additives. Further studies on the release of hydrophobic organic additives and their transformation products under various conditions are required to extend our understanding of the environmental fate and transport of these additives in aquatic environments.

Estimating the Bioaccumulation Potential of Hydrophobic Ultraviolet Stabilizers Using Experimental Partitioning Properties.

Although hydrophobic ultraviolet (UV) stabilizers are an emerging environmental concern because of their widespread occurrence, persistence, and bioaccumulation potential, experimental values of their partitioning properties required for risk assessment are scarce. In this study, n-octanol-water partition (Kow) and lipid-water partition constants (Klipw), which are key parameters for environmental risk assessment, were experimentally determined for five selected hydrophobic UV stabilizers (UV326, UV327, UV328, UV329, and UV531) based on third-phase partitioning among polydimethylsiloxane (PDMS), water, and n-octanol/lipid. The partition constants between PDMS and water (KPDMSw), obtained using the dynamic permeation method were used to derive Kow and Klipw. The obtained log Kow and log Klipw values were in the ranges of 7.08-7.94 and 7.50-8.34, respectively, indicating that the UV stabilizers exhibited a high bioaccumulation potential in aquatic environments. The experimental Kow and Klipw values obtained in this study provide valuable information for the evaluation of the fate, distribution, bioavailability, and toxicity of the UV stabilizers in aquatic environments.

Equilibrium leaching of selected ultraviolet stabilizers from plastic products.

Despite the importance of (micro)plastics in the release of plastic additives, the leaching mechanism of organic plastic additives from various plastic materials is poorly understood. In this study, the equilibrium leaching of five highly hydrophobic ultraviolet (UV) stabilizers (UV326, UV327, UV328, UV329, and UV531) from three plastics (low-density polyethylene (LDPE), polyethylene terephthalate (PET), and polystyrene (PS)), was investigated employing acetonitrile-water cosolvent systems. Their extrapolated water solubilities were in the 0.15-0.54 µg L-1 range, limiting their transport as "dissolved" in water and (micro)plastics are likely those particulate carriers. The equilibrium leaching of UV stabilizers from plastics was better explained by the Flory-Huggins model incorporating the nonideal behavior caused by the size disparity between UV stabilizers and polymer materials and their compatibility. Specifically, leaching of UV stabilizers from LDPE showed a positive deviation from Raoult's law, whereas slight negative deviations were observed in PET and PS. In addition, the equilibrium concentration of the benzotriazoles in LDPE increased linearly with the volume fraction up to only 0.4%. These observations could be explained by the unfavorable interactions of UV stabilizers with polyethylene, indicating that polymer type should be also important when evaluating the fate of hydrophobic additives. Because equilibrium distribution of additives between (micro)plastics and water is crucial for evaluating the fate and transport of hydrophobic plastic additives, further studies on the leaching equilibrium of various additives from different plastic materials are necessary.

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.

Background: Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminium hydroxide adjuvant. Methods: We conducted a dose-escalation, open label trial (phase 1) and a randomized, double-blind, placebo-controlled trial (phase 2) to evaluate the safety and immunogenicity of the Nanocovax vaccine (in 25 mcg, 50 mcg, and 75 mcg doses, aluminium hydroxide adjuvanted (0·5 mg/dose) in 2-dose regime, 28 days apart (ClinicalTrials.gov number, NCT04683484). In phase 1, 60 participants received two intramuscular injection of the vaccine following dose-escalation procedure. The primary outcomes were reactogenicity and laboratory tests to evaluate the vaccine safety. In phase 2, 560 healthy adults received either vaccine doses similar in phase 1 (25 or 50 or 75 mcg S antigen in 0·5 mg aluminium per dose) or adjuvant (0·5 mg aluminium) in a ratio of 2:2:2:1. One primary outcome was the vaccine safety, including solicited adverse events for 7 day and unsolicited adverse events for 28 days after each injection as well as serious adverse event or adverse events of special interest throughout the study period. Another primary outcome was anti-S IgG antibody response (Index unit/ml). Secondary outcomes were surrogate virus neutralisation (inhibition percentage), wild-type SARS-CoV-2 neutralisation (dilution fold), and T-cell responses by intracellular staining for interferon gamma (IFNg). Anti-S IgG and neutralising antibody levels were compared with convalescent serum samples from symptomatic Covid-19 patients. Findings: For phase 1 study, no serious adverse events were observed for all 60 participants. Most adverse events were grade 1 and disappeared shortly after injection. For phase 2 study, after randomisation, 480 participants were assigned to receive the vaccine with adjuvant, and 80 participants were assigned to receive the placebo (adjuvant only). Reactogenicity was absent or mild in the majority of participants and of short duration (mean ≤3 days). Unsolicited adverse events were mild in most participants. There were no serious adverse events related to Nanocovax. Regarding the immunogenicity, Nanocovax induced robust anti-S antibody responses. In general, there humoral responses were similar among vaccine groups which reached their peaks at day 42 and declined afterward. At day 42, IgG levels of vaccine groups were 60·48 [CI95%: 51·12-71·55], 49·11 [41·26-58·46], 57·18 [48·4-67·5] compared to 7·10 [6·32-13·92] of convalescent samples. IgG levels reported here can be converted to WHO international standard binding antibody unit (BAU/ml) by multiplying them to a conversion factor of 21·8. Neutralising antibody titre of vaccine groups at day 42 were 89·2 [52·2-152·3], 80·0 [50·8-125.9] and 95·1 [63·1-143·6], compared to 55·1 [33·4-91·0] of the convalescent group. Interpretation: Up to day 90, Nanocovax was found to be safe, well tolerated, and induced robust immune responses. Funding: This work was funded by the Coalition for Epidemic Preparedness Innovations (CEPI), the Ministry of Science and Technology of Vietnam, and Nanogen Pharmaceutical Biotechnology JSC.